FDA risk communication strategy
This article was originally published in The Tan Sheet
The Risk Communication Advisory Committee discusses the agency's draft risk communication strategic plan and offers further advice on strategic priorities for research on effective risk communication in a meeting scheduled for April 30 and May 1. Presentations from the public are scheduled between 1 p.m. and 2 p.m. the first day and 10:30 a.m. to 11:30 a.m. the next day during the meeting at an FDA facility in Rockville, Md., according to a March 5 Federal Register notice. At its previous meeting, the committee emphasized that FDA should assess its communications to ensure safe and effective use of medical products (1"The Tan Sheet" Sept. 1, 2008, p. 8)
You may also be interested in...
FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.